Cardiome Pharma in der analyse

Cardiome Announces Commercialization Partnership For BRINAVESS™ In Select European Markets

http://www.newswire.ca/en/story/1193843/...in-select-european-markets  

Ich denke es ist nur eine Frage der Zeit bis hier der Kurs wieder massiv anzieht,
in biotuesdays wurde Hunter interviewt: http://biotuesdays.com/2013/06/25/how-ma...brinavess/

Das Marktpotential für Brinavess IV in Europa ist ca 50- 100 Mio in den USA ca 250 Mio
nur für Brinavess IV (Intranvös). Das Potenzial für die Orale Form liegt um ein vielfaches höher. Und Cardiome wäre bereit die Studie für die Orale Form zu starten, die Pillen liegen Verpackungsbereit...alles in diesem Interview nachzulesen.

 

Das sehe ich genauso wie du,unser Baby lernt gerade langsam wieder laufen,Kurs zieht an !!

MFG
Chjali  

müsste der Kurs nach dem Rerssplit noch 5mal höher sein!  

Nicht aufgeben hier,bei biotech ist alles möglich,schaut euch nur Acadia an,deren "Pimavanserin" war in Phase-3 durchgefallen und die Aktie ist auf 50 cent abgeschmiert und lag da jahrelang,bis erneut in neuer Phase-3 plötzlich top line Results für das gleiche Medi da waren,und die Aktie ..........  

http://www.newswire.ca/en/story/1225729/...-for-brinavesstm-in-the-eu

Das könnte ein wenig Schub geben!  

Cardiome Pharma announced that its subsidiary, Cardiome Development, has entered into an agreement with Tzamal Medical, to sell and distribute Brinavess exclusively in Israel. Under the terms of the agreement, Tzamal Medical has agreed to specific annual commercial goals for Brinavess. Financial details of the agreement have not been disclosed. The initial term of this commercial agreement begins September 15 for the duration of three years and is renewable on an annual basis thereafter.

Mfg
Chali  

Anstieg heute :D

3.17
+0.63 (24.80%)
 

verstehs wiedermal nicht, wieso jetzt alle werfen und am besten gleich noch die stopp loss auslösen...

halten, halten, halten....was wollt ihr mit 100.- Gewinn?  

VANCOUVER, Sept. 23, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced publication of positive data from an open label study in patients with atrial fibrillation that compared treatment with vernakalant intravenous (IV) to oral propafenone and oral flecainide. Patients treated with vernakalant achieved conversion to normal sinus rhythm in a median time of 12 minutes compared to 151 minutes for the propafenone group and 162 minutes for the flecainide group (p

"I am pleased that the favorable results of this study show that in patients with recent onset atrial fibrillation, treatment with vernakalant IV was associated with more rapid conversion to normal sinus rhythm than propafenone or flecainide, both of which are frequently prescribed antiarrhythmic medications," stated William Hunter, M.D., Chief Executive Officer of Cardiome Pharma Corp. "The faster conversion rate with intravenous vernakalant experienced at this center translated to shorter length of stay in the emergency room compared to the other two therapies and we believe these results can be replicated across other centers worldwide in similar patient groups."

"Vernakalant IV, with its fast onset of action, is a well-tolerated and effective alternative to propafenone or flecainide in this patient population," stated Diego Conde, M.D., Chief of Cardiovascular Emergency Care Section, Instituto Cardiovascular de Buenos Aires. "The significant advantage in time to conversion to normal sinus rhythm with vernakalant compared to propafenone or flecainide, that leads to a reduction in hospital stay-length may result in patient benefits," Dr. Conde added.

Patients with symptomatic recent onset atrial fibrillation (less than 48 hours duration) without structural heart disease or hemodynamic instability were eligible for the study. Subjects received a single oral dose of 600 mg of propafenone (N=50), a single oral dose of 300 mg of flecainide (N=50), or vernakalant IV (N=50) in an initial dose of 3.0 mg/kg for 10 minutes and an additional 2 mg/kg if atrial fibrillation had not resolved within 15 minutes. The conversion rate approximated 80% in both the propafenone and flecainide groups at 8 hours versus 90% in the vernakalant group at 2 hours. This difference was not statistically significant at 8 hours. In addition to the more rapid time to cardioversion, patients treated with vernakalant IV experienced a significantly shorter median hospital length of stay, 243 minutes (interquartile range [IQR], 190-276) versus 422 minutes (IQR, 341- 739) for the patients treated with propafenone and 410 minutes (IQR, 330-727) for the patients treated with flecainide (p1

MFG
Chali

 

tönt doch sensationell.
und jetzt bitte einfach mal alle einige Tage halten!!!
 

Hoch J 4.03 23.09.2013
Hoch VJ 13.40 03.01.2012  

kommt der Rebound :)  

Cardiome Pharma Corp. : Cardiome Announces Commercialization Partnership with LifePharma (Z.A.M) Ltd. for BRINAVESS(TM) in Cyprus

NASDAQ: CRME   TSX: COM

VANCOUVER, Sept. 24, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS(TM) (vernakalant intravenous) exclusively in Cyprus. Under the terms of the agreement, LifePharma has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement were not disclosed.

"We are pleased to enter into this agreement with LifePharma and continue to have BRINAVESS available to our customers in Cyprus," said Karim Lalji, Cardiome's Chief Commercial Officer. "LifePharma is a pharmaceutical industry leader in Cyprus and we are excited to leverage their deep expertise in this market."

"We are pleased to have partnered with Cardiome to commercialize BRINAVESS in Cyprus," said Savvas Jacovides, President of the Board of Directors of LifePharma (Z.A.M) Ltd. "Our customers will be delighted to know that access to BRINAVESS will continue through LifePharma and that we are committed to meeting their needs to have the product available."

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.  

VANCOUVER , Sept. 25, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that BRINAVESS™ (vernakalant intravenous) has been approved in Turkey by the Turkish Ministry of Health for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. The Turkish Ministry of Health oversees the regulation of medicines in Turkey .

"We are pleased to receive approval for BRINAVESS in Turkey ," said Karim Lalji , Cardiome's Chief Commercial Officer. "This decision confirms Cardiome's commitment to pursue BRINAVESS approvals beyond the EU region. We will seek a local distribution partnership in this key market in order to optimize the commercialization and launch and make BRINAVESS available for the benefit of patients suffering from AF."

Turkey is a significant emerging market in the pharmaceutical industry. According to the European Federation of Pharmaceutical Industry and Associations Pharmaceutical Industry Report, total sales for the pharmaceutical market in Turkey totaled €7.2B1 in 2011.  

Nach dem heftigen Anstieg, das gefällt mir:-)
Hier liegt noch viel nach oben drin!  

... kann man tatsächlich in solche Werte investieren, ohne im Ansatz zu schnallen, was die Firma herstellt und wie aussichtsreich der wirtschaftliche Erfolg ist?

Du scheinst jeweils nach Peergroup zu gehen. Daher nimmst Du die Zahlen. Aber kann man das so machen? Nur weil andere Firmen im gleichen Segment höher bewertet sind, schließt man, dass auch diese hier bei Erfolg mit dem nächsten Produktknaller auf eine ähnliche Höhe aufschließt. Wie tief guckst Du denn in die Firmenzahlen rein?
Oder geht es auch hier letztlich um Zockerei, nach Gefühl?  

Nein,auf keinen Fall !

Cardiome hat 20 mio cash,ist gut finanziert und hat mit Brinavess einen Herzmedikament Blockbuster in der EU Vermarktung,die wie am Schnürchen klappt ! In zukunft kommt noch die US zulassung desselben Medikaments und dann gehts hier erst richtig ab !! Denn Cardiome ist nur schlappe 40 Mio.-$ wert,also geschenkt ! Über das Potential des Medikaments hab ich im Eingangsposting (nr.1) ausführlich berichtet,ich bin und bleibe dabei !

MFG
Chali  

Und von den dreien (Affymetrix, Lpath und Cardiome), wo hast Du z.Zt. Deine Kohle stehen? Und seit wann?  

8:46AM Cardiome Pharma receives approval for BRINAVESS in South Africa (CRME) 3.62 : Co announced that BRINAVESS (vernakalant intravenous) has been approved in South Africa by the Medicines Control Council (MCC) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The MCC oversees the regulation of medicines in South Africa

MFG
Chali  

Seltsam. Vermutlich wegen USA Haushaltsproblem, hm?  

Wenn man den 2-Jahres-Chart ansieht, entdeckt man eine "blühende Vergangenheit" und fragt sich, was war damals besser. Also gucke ich nach Ergebniszahlen und da erkennt man was. In die roten Zahlen ging es im Frühjahr 2012, bzw es ließ sich wohl nicht länger schönreden.

Diese Jahr sieht gemischt aus. Q1 18.4 M plus, aber Q2 meldet 2.8 M minus. Was wird der Herbst bringen?

We recorded a net income of $18.4 million ($1.47 per common share) for the three months ended March 31, 2013 (Q1-2013), compared to a net loss of $7.0 million ($0.57 per common share) for the three months ended March 31, 2012 (Q1-2012). The net income for Q1-2013 was primarily due to the recognition of a $20.8 million gain on the settlement of debt owed to Merck. The net loss for Q1-2012 was due to restructuring charges, clinical development efforts, pre-clinical research projects, as well as other operating costs.

Cardiome reported a net loss of $2.8 million ($0.22 per common share) for the three months ended June 30, 2013 (Q2-2013), compared to a net loss of $5.7 million ($0.46 per common share) for the three months ended June 30, 2012 (Q2-2012).

Total revenue for Q2-2013 was $0.1 million as compared to $0.2 million in Q2-2012.

Research and development expenditures were insignificant for Q2-2013 compared to $2.3 million for Q2-2012. Selling, general and administration (SG&A) expenditures for Q2-2013 were $3.0 million compared to $2.2 million for Q2-2012. Effective Q1-2013, SG&A expenses include costs incurred to support the commercialization of BRINAVESSTM (vernakalant intravenous). We did not incur any interest expense during Q2-2013 as a result of the settlement of debt owed to Merck, known as MSD outside the United States and Canada. Interest expense for Q2-2012 was $1.1 million.

 

Wir knabbern an der 4 dollar Marke !! Uns das an einem grottenschlechten Börsentag wie heute !! Ich mach erst mal ein Fass auf,denn mein Verkaufskurs liegt immer noch locker 1000% höher,aber das dürfte bei Cardiome kein Problem sein .....

MFG
Chali  

 

Cardiome Announces Publication of Positive Data from an Observational, Retrospective Study of BRINAVESS
NASDAQ: CRME TSX: COM

VANCOUVER, Oct. 7, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced publication of positive data from an observational, retrospective study performed at the Skåne University Hospital in Malmö, Sweden. The study included 251 recent-onset atrial fibrillation (AF) patients who received 355 BRINAVESS™ treatments during the period between January 15, 2011 and April 15, 2013. During the observation period, 70% of the AF patients treated with BRINAVESS converted with a median time of 11 minutes. Conversion efficacy was 76% in patients with AF duration

"It is exciting to see that patients treated in the clinically critical first 48 hours after AF onset appear to continue to derive better-than-expected benefit from BRINAVESS and that they also prefer this therapy over DC cardioversion," stated William Hunter, M.D., Chief Executive Officer of Cardiome Pharma Corp. "The high conversion efficacy coupled with short hospital stay we believe makes BRINAVESS a practical option for physicians and patients who value rapid relief from AF."

"Skåne University Hospital developed a "fast-track" AF program in the emergency room where patients with short duration AF were promptly treated with BRINAVESS, which likely contributed to the higher efficacy seen in this setting compared to the ACT and AVRO clinical trials," stated Dr. Steen Juul-Möller, the study's Principal Investigator and Cardiome's Medical Director. "The finding that 75% of successfully treated BRINAVESS patients remained in normal sinus rhythm after a one year follow-up period - was an extremely interesting and important finding that requires further investigation," added Dr. Juul-Möller.

Patients with recent-onset AF and whom cardioversion was considered were evaluated for BRINAVESS treatment. Over the period of the study, 251 patients received 355 treatments. In all patients, 70% of BRINAVESS treatments were successful and 70% of the patients responded at least once with conversion to sinus rhythm. The conversion rate was higher at 76% among patients with AF duration 10 hours (P1

Those patients who did not respond to BRINAVESS treatment were subsequently treated with DC cardioversion. All patients who had experienced both BRINAVESS and DC cardioversion were given a questionnaire to assess cardioversion preference and were followed up for a maximum period of 27 months (BRINAVESS [n = 156]; DC cardioversion [n=91]). Among those who converted with BRINAVESS, 72% would prefer this treatment, in patients who did not convert with BRINAVESS, 61% said they would prefer DC cardioversion if they experienced a relapse (P

References:

1.Juul-Möller, S. Vernakalant in recently developed Atrial Fibrillation: How to translate pharmacological trials into clinical practice. European Journal of Cardiovascular Medicine. Vol. 2, Issue 4. Published online October 4, 2013